Abstract:Objective: To explore the clinical characteristics and related influencing factors of depression and cognitive dysfunction in patients with Parkinson's disease (PD). Methods: A total of 117 PD patients treated in the hospital from January 2019 to June 2020 were enrolled as the research subjects. The depression of patients was evaluated by Hamilton Depression Scale (HAMD), and the clinical characteristics and influencing factors of depression were analyzed. The cognitive status of patients was assessed by Montreal Cognitive Assessment (MOCA), and the clinical characteristics and influencing factors of cognitive dysfunction were analyzed. Results: The average score of HAMD and detection rate of depression were (17.64±3.26) points and 58.12%, respectively. Depression was related to course of disease, Hoehn-Yahr staging, education level and MoCA score (P<0.05). The results of multivariate Logistic regression analysis showed that course of disease, Hoehn-Yahr staging, education level and MoCA score were independent influencing factors of depression (P<0.05). The average score of MoCA and detection rate of cognitive dysfunction were (26.25±3.82) points and 53.85%, respectively. Cognitive dysfunction was related to gender, course of disease, age, Hoehn-Yahr staging, onset symptoms (festination, freezing, salivation and postural hypotension) and MoCA score (P<0.05). The results of multivariate Logistic regression analysis showed that Hoehn-Yahr staging and MoCA score were independent influencing factors of cognitive dysfunction (P<0.05). Conclusion: The detection rates of depression and cognitive dysfunction are relatively high in patients with Parkinson's disease. Depression is easily affected by course of disease, Hoehn-Yahr staging, education level, and MoCA score, while cognitive dysfunction is easily affected by Hoehn-Yahr staging and HAMD score, which deserves attention.
曾敏, 李梦岚, 陈静, 李银萍. 帕金森患者抑郁及认知功能障碍的临床特点及相关因素分析[J]. 河北医学, 2022, 28(3): 465-472.
ZENG Min, LI Menglan, CHEN Jing, et al. Clinical Characteristics and Related Factors of Depression and Cognitive Dysfunction in Patients with Parkinson's Disease. HeBei Med, 2022, 28(3): 465-472.
[1] Honma M.Impairment of cross-modality:a new cognitive dysfunction in parkinson's disease[J].Brain Nerve,2018,70(11):1157~1163. [2] Weil RS,Winston JS,Leyland LA,et al.Neural correlates of early cognitive dysfunction in parkinson's disease[J].Ann Clin Transl Neurol,2019,6(5):902~912. [3] Kalbe E,Aarsland D,Folkerts AK.Cognitive interventions in parkinson's disease:where we want to go within 20 years[J].Parkinsons Dis,2018,8(1):107~113. [4] Baiano C,Barone P,Trojano L,et al.Prevalence and clinical aspects of mild cognitive impairment in parkinson's disease:a meta-analysis[J].Mov Disord,2020,35(1):45~54. [5] Cerri S,Mus L,Blandini F.Parkinson's disease in women and men:what's the difference[J].Parkinsons Dis,2019,9(3):501~515. [6] Sezgin M,Bilgic B,Tinaz S,et al.Parkinson's disease dementia and lewy body disease[J].Semin Neurol,2019,39(2):274~282. [7] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,47(6):428~433. [8] Boessen R,Groenwold RH,Knol MJ,et al.Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials[J].Affect Disord,2013,145(3):363~369. [9] Sollinger AB,Goldstein FC,Lah JJ,et al.Mild cognitive impairment in parkinson's disease:subtypes and motor characteristics[J].Parkinsonism Relat Disord,2010,16(3):177~180. [10] Ryan M,Eatmon CV,Slevin JT.Drug treatment strategies for depression in parkinson disease[J].Expert Opin Pharmacother,2019,20(11):1351~1363. [11] 陈芳萍,朱雪娇.帕金森病患者的平衡功能变化及其相关因素分析[J].中华全科医学,2018,16(6):925~928. [12] 陈诚,王惠玲,王高华,等.抑郁症与精神分裂症患者静息态功能磁共振成像与认知功能的差异[J].中华精神科杂志,2020,53(5):377~383. [13] Weil RS,Winston JS,Leyland LA,et al.Neural correlates of early cognitive dysfunction in Parkinson's diseasep[J].Ann Clin Transl Neurol,2019,6(5):902~912. [14] 刘淑娟.左旋多巴治疗帕金森疗效减退的影响因素分析[J].临床医学,2021,41(7):40~42. [15] 袁德智,胡洁,赵秋叶,等.帕金森病进展速度与抑郁、睡眠障碍的相关性分析[J].中国医科大学学报,2020,49(4):326~330.